FDA Letter API

Huntington Beach Vape Shop

Letter data

Company
Huntington Beach Vape Shop
Recipient
Jim Petty | Huntington Beach Vape Shop | 365 Pilot Road | Suite B | Las Vegas | , | NV | 89119 | United States | jim.petty@icloud.com | iyad.sabbah77@gmail.com
Issue date
2018-10-24
Posted date
Not available
FDA office
Center for Tobacco Products
Subject
Not available
Product
Tobacco
CMS ID
562781
Reference number
1800927
FEI
Not available
Inspection dates
2018-09-19 to 2018-10-02

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Huntington Beach Vape Shop MARCS-CMS 562781 — October 24, 2018 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UPS and Electronic Mail Reference #: 1800927 Product: Tobacco Recipient: Recipient Name Jim Petty Huntington Beach Vape Shop 365 Pilot Road Suite B Las Vegas , NV 89119 United States jim.petty@icloud.com iyad.sabbah77@gmail.com Issuing Office: Center for Tobacco Products 10903 New Hampshire Avenue Silver Spring , MD 20993 United States Dear Jim Petty: On September 12, 2018, the United States Food and Drug Administration's (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter informing you that your Candy King Batch e-liquid product is misbranded under section 903(a)(1) and/or 903(a)(7)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because its labeling and/or advertising is false or misleading. Specifically, FDA determined that the labeling and/or advertising of your Candy King Batch e-liquid is misleading under section 903(a)(1) and/or 903(a)(7)(A) of the FD&C Act because it causes the product to imitate food products, particularly ones that are marketed toward, and/or appealing to, children. On September 19, 2018 and October 2, 2018, you sent FDA a response to the Warning Letter. In response to the Warning Letter, you stated you implemented corrective actions to address the violation identified in the Warning Letter. Based on our evaluation, it appears that you have taken steps to address the violations identified in the Warning Letter. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future. Should you have any questions or concerns, please contact me at (301) 796-9235 or by email at elenita.ibarrapratt@fda.hhs.gov . Sincerely, /S/ Ele Ibarra-Pratt Division Director Office of Compliance and Enforcement Center for Tobacco Products VIA UPS and Electronic Mail cc: Azim Chowdhury Keller and Heckman LLP 1001 G Street NW, Suite 500 West Washington, DC 20001 chowdhury@khlaw.com GoDaddy, LLC abuse@godaddy.com Shopify, Inc. abuse@shopify.com Content current as of: 04/11/2019 Regulated Product(s) Tobacco